However, these inhibitors are toxic, ineffective against other Kras mutations (such as the Q61L mutation found in the A/J lung cancer model or the predominant G12D mutation found in pancreatic cancer), or have not been explored in the context of the tumor microenvironment [78]. This evidence concerns the gene KRAS and lung carcinoma.